About 5-hydroxytryptamine receptor 2A
5-hydroxytryptamine receptor 2A (HTR2A) is a protein
from Homo sapiens identified by UniProt accession
P28223, 471 residues long.
MolForge cross-references it against 0 known binders and
478 disease associations.
Target properties
| Protein name | 5-hydroxytryptamine receptor 2A |
| UniProt accession | P28223 |
| Gene | HTR2A |
| Organism | Homo sapiens |
| Length | 471 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (478)
Diseases linked to this target (Open Targets).
- major depressive disorder · score 0.63
- schizophrenia · score 0.62
- unipolar depression · score 0.61
- bipolar disorder · score 0.61
- psychosis · score 0.61
- autism · score 0.61
- schizoaffective disorder · score 0.61
- bipolar I disorder · score 0.60
- Agitation · score 0.60
- depressive disorder · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P28223-F1 | alphafold | PREDICTED | 73.74 | — |
Amino-acid sequence (471 residues)
MDILCEENTS LSSTTNSLMQ LNDDTRLYSN DFNSGEANTS DAFNWTVDSE NRTNLSCEGC LSPSCLSLLH LQEKNWSALL TAVVIILTIA GNILVIMAVS LEKKLQNATN YFLMSLAIAD MLLGFLVMPV SMLTILYGYR WPLPSKLCAV WIYLDVLFST ASIMHLCAIS LDRYVAIQNP IHHSRFNSRT KAFLKIIAVW TISVGISMPI PVFGLQDDSK VFKEGSCLLA DDNFVLIGSF VSFFIPLTIM VITYFLTIKS LQKEATLCVS DLGTRAKLAS FSFLPQSSLS SEKLFQRSIH REPGSYTGRR TMQSISNEQK ACKVLGIVFF LFVVMWCPFF ITNIMAVICK ESCNEDVIGA LLNVFVWIGY LSSAVNPLVY TLFNKTYRSA FSRYIQCQYK ENKKPLQLIL VNTIPALAYK SSQLQMGQKK NSKQDAKTTD NDCSMVALGK QHSEEASKDN SDGVNEKVSC V
Explore 5-hydroxytryptamine receptor 2A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets